| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | NFH |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human NEFH |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NEFH抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Neurofilament ELISA validation in CSF: A biomarker for neurodegeneration*
**作者**: Petzold A, et al.
**摘要**: 该研究验证了NEFH抗体在脑脊液(CSF)中检测神经丝重链(NF-H)的可靠性，发现NF-H水平升高与肌萎缩侧索硬化症(ALS)和多发性硬化症等神经退行性疾病相关，提示其作为神经轴突损伤的生物标志物潜力。
---
2. **文献名称**: *Comparative analysis of neurofilament antibodies in ALS diagnosis*
**作者**: Brettschneider J, et al.
**摘要**: 通过比较多种NEFH抗体的敏感性和特异性，研究发现某些抗体在ALS患者血清和CSF中检测神经丝蛋白的效果更优，强调了抗体选择对临床诊断准确性的重要性。
---
3. **文献名称**: *Neurofilament heavy chain as a marker of axonal injury in Alzheimer's disease*
**作者**: Gendron TF, et al.
**摘要**: 该文献探讨了NEFH抗体在阿尔茨海默病患者脑组织中的应用，显示NF-H的异常聚集与轴突退行性病变相关，为研究tau蛋白病理机制提供了新视角。
---
4. **文献名称**: *Antibody cross-reactivity in neurofilament assays: Challenges and solutions*
**作者**: Khalil M, et al.
**摘要**: 研究揭示了部分NEFH抗体可能与其他神经丝蛋白(如NF-L/M)发生交叉反应，建议结合质谱技术优化检测方法以提高特异性，避免假阳性结果。
---
以上文献涵盖NEFH抗体的生物标志物验证、诊断应用、病理机制研究及技术挑战，可支撑神经退行性疾病研究或实验方法优化。
**Background of NEFH Antibody**
The neurofilament heavy polypeptide (NEFH) antibody is a critical tool in neuroscience and pathology research, targeting the heavy subunit of neurofilaments (NF-H), a major component of the neuronal cytoskeleton. Neurofilaments, composed of three subunits (NF-L, NF-M, and NF-H), are type IV intermediate filaments predominantly expressed in mature neurons. They play essential roles in maintaining axonal structural integrity, regulating diameter, and facilitating intracellular transport.
NEFH, the largest subunit (~200 kDa), contains a unique carboxy-terminal domain with multiple phosphorylation sites. These modifications influence neurofilament assembly, stability, and interactions with other cytoskeletal components. Antibodies against NEFH are widely used to detect axonal damage in neurological disorders, such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and traumatic brain injury, where neurofilament accumulation or abnormal phosphorylation is observed.
In research, NEFH antibodies are employed in techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to visualize neuronal morphology, assess neurodegeneration, and study disease mechanisms. Commercially available NEFH antibodies include monoclonal and polyclonal variants, often validated for specificity across species (human, mouse, rat). Their utility extends to biomarker studies, as elevated neurofilament levels in biofluids correlate with neuronal injury, aiding diagnostic and therapeutic monitoring. However, cross-reactivity with other intermediate filaments or phosphorylated epitopes requires careful validation to ensure accurate interpretation. Overall, NEFH antibodies remain indispensable for exploring neuronal health and disease.
×
